Pioneering Cancer Prevention Program Launched In New York

A prevention program serving an ethnically diverse population of women at high risk of cancer is detailed in an article published Monday 23 March in the online peer-reviewed journal ecancer. The article describes a screening program to identify women from underserved communities who are at a high risk of developing breast or ovarian cancer; a […]

Breast tissue evaluation with fine-needle aspiration fast tracks cancer Rx planning

BARBARA BOUGHTON Despite its limitations, FNA offers lower cost, less invasion, and fewer complications. Experts discuss why they chose FNA over core biopsy. In the past decade, core biopsy has largely replaced fine-needle aspiration for breast tissue evaluation. The latter technique’s inability to distinguish between invasive cancer and in situ cases and a general unease […]

Anthracycline Cardiotoxicity: Why Are We Still Interested?

Anthracycline cardiotoxicity has been of clinical concern for more than 3 decades. Many hundreds of papers have been written about this unusual form of toxic cardiomyopathy, and yet, we are still putting pieces of the puzzle together. Our cumulative knowledge helps us to predict the risk of cardiac damage with fair accuracy for most patients, […]

Anthracycline-­Induced Cardiotoxicity: Risk Assessment and Management

In the current issue of ONCOLOGY, Hershman and Shao provide a comprehensive review of anthracycline-induced cardiotoxicity (AIC). Risk factors for AIC include age (??18 or ??65 years) at time of treatment, increasing cumulative dose or dose intensity of anthracyclines, mediastinal radiation therapy (RT), and female gender.[1-4] The Surveillance, Epidemiology and End Results (SEER)-Medicare database showed […]

The Challenges of Improving Breast Cancer Outcome With Diagnostic Imaging Techniques

Positron-emission tomography (PET) technology has drastically improved in the past few years, with the development of hybrid imaging devices combining PET and computed tomography (CT), which have essentially replaced stand-alone PET scanners in most centers. Image quality has also increased with the use of improved PET detectors and image reconstruction techniques. While a few years […]

ARIMIDEX Offers Women Greater Protection Against HR+ Early Breast Cancer Returning In The 1st 2 Yrs

“Anastrozole is the only aromatase inhibitor (AI) which has now been shown to prevent recurrences in women with hormone receptor positive early breast cancer both during the initial high-risk two years after surgery, and also well beyond the completion of treatment. In breast cancer there are no guarantees and we can’t predict which women will […]

Women With Early Breast Cancer To Receive The Most Up-to-date Information Available, Australia

National Breast and Ovarian Cancer Centre (NBOCC) has now released the eagerly anticipated revised version of its Guide for women with early breast cancer. The comprehensive, 200 page resource provides information to support women with early breast cancer* in making decisions about their treatment and care, as well as advice for family and friends. The […]

Cephalon Response To NICE Guidance On Advanced Breast Cancer Treatment Published 25 February 2009, UK

Liz Hardaker, medical director of Cephalon UK. “We are disappointed and surprised that NICE has not taken this opportunity to distinguish between different forms of anthracycline treatment; specifically the use of liposomal-encapsulated doxorubicin. “Myocet, in combination with cyclophosphamide, is indicated for the first line treatment of metastatic breast cancer in women (SmPC). A number of […]

Systematic Estimation Of Breast Cancer Risk Appears Justified In Postmenopausal Women

Screening for breast cancer risk in all postmenopausal women, using a combination of risk factors and breast density, can identify women at high risk of disease, according to systematic literature reviews and meta-analyses reported in the March 10 online issue of the Journal of the National Cancer Institute. The reviews and meta-analyses also support the […]

Herceptin Proven To Benefit Women With HER2 Positive Early Breast Cancer Latest Results From The HERA Study

Study confirms Herceptin’s promise of extra years of living cancer free The Breast International Group (BIG) in collaboration with Roche announced that women with HER2 positive early breast cancer continue to benefit from Herceptin (trastuzumab) several years after treatment completion and as a result enjoy a longer life disease free. The patients were treated for […]